Single- and multi-tablet HIV regimens go head-to-head
"Many of us [clinicians] default to using single-tablet regimens."
By
Alun Evans
August 26, 2026
Clinical Scorecard: Single- and multi-tablet HIV regimens go head-to-head
At a Glance
Category Detail
Condition HIV Key Mechanisms Viral suppression defined as HIV RNA level below 200 copies/mL. Target Population Adults with HIV enrolled in Washington state Medicaid. Care Setting HIV treatment and management in Medicaid programs.
Key Highlights
90.4% of Medicaid enrollees achieved viral suppression. No statistically significant difference in suppression rates between single-tablet and multi-tablet regimens. Housing status significantly impacts viral suppression rates. Bictegravir/emtricitabine/tenofovir alafenamide is 77% more expensive than some multi-tablet alternatives. Cost considerations should be integrated into treatment decisions. Guideline-Based Recommendations
Diagnosis
Viral suppression should be monitored as a key outcome in HIV treatment. Management
Consider both cost and patient preferences when selecting HIV regimens. Monitoring & Follow-up
Regular assessment of housing stability as it correlates with treatment adherence. Risks
Unstable housing is associated with lower rates of viral suppression. Patient & Prescribing Data
Adults with HIV in Washington state Medicaid.
Single-tablet regimens may not provide significant clinical advantages over multi-tablet regimens.
Clinical Best Practices
Integrate cost information into treatment decision-making. Address social determinants of health, such as housing stability, in treatment plans. Encourage adherence strategies that consider patient circumstances. Related Resources & Content
